微生态制剂预防新生儿抗生素相关性腹泻的临床研究  

Microeological Modulator in Preventing Neonatal Antibiotic Associated Diarrhea:A Clinical Research

作　　者：柯丹红[1] 高璇璇[1] 李联侨[1] 

机构地区：[1]泉州市儿童医院新生儿科,福建泉州362000

出　　处：《中华医院感染学杂志》2009年第10期1211-1213,共3页Chinese Journal of Nosocomiology

摘　　要：目的探讨微生态制剂培菲康对新生儿抗生素相关性腹泻(AAD)的预防效果。方法对2004年1月-2007年12月住院即开始应用抗菌药物的新生儿,前瞻性分组对照研究,在原发病治疗的基础上,治疗组加予预防性应用培菲康散剂。结果培菲康治疗组996例,发生抗生素相关性腹泻71例,发病率7.13%;对照组1012例,发生AAD235例,发病率23.22%,两组对比差异有统计学意义(χ2=99.402,P<0.01)。结论微生态制剂(培菲康)对于预防新生儿AAD具有明显的效果,可显著降低AAD的发病率,值得临床推广应用。OBJECTIVE To understand the clinical effect of microeclogical modulator Bifid Triple Viable （BTV） in preventing neonatal antibiotic associated diarrhea （AAD）. METHODS A prospective controlled study was undertaken on the antibiotic treated group and control group from Jan, 2004 to Dec 2007. RESULTS Among the 996 neonatal patients in treated group, 71 patients occurred AAD, with the morbidity of 7.13%. Among the 1012 neonatal patients in control group, 235 patients occurred AAD （morbidity 23. 22%）. There was significant difference between the two groups （P〈0.01）. CONCLUSIONS It shows obvious clinical effect of microecological moducator BTV on neonatal AAD to reduce the morbility.

关 键 词：微生态制剂 抗生素相关性腹泻病 新生儿 

分 类 号：R181.32[医药卫生—流行病学]